Latest News and Press Releases

Novel combination achieves 60.8% response rate and 90.2% disease control rate in first-line non-small cell lung cancer (1L NSCLC)Notably, ~92% of all evaluable patients have PD-L1 TPS <50%,...

Complementary nature of these two immunotherapies leads to excellent 17.6-month median Overall Survival in head and neck cancer patients with PD-L1 CPS <1Mature overall survival data builds on...

Media Release First patient safely dosed in TACTI-004 Phase III lung cancer trial, marking a significant milestonePivotal TACTI-004 trial design presented at the European Lung Cancer Congress (ELCC)...

SYDNEY, AUSTRALIA , April 02, 2025 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune...

First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for ImmutepGlobal Phase III with efti will enrol approximately 756 patients at more than...

SYDNEY, AUSTRALIA, March 20, 2025 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune...

Media Release Marking Immutep’s transition to a Phase III biotech, the Company’s pivotal TACTI-004 trial in first-line non-small cell lung cancer (1L NSCLC) received first regulatory approvalMature...

Phase II trial evaluating efti in combination with radiotherapy plus KEYTRUDA® (pembrolizumab) in patients with soft tissue sarcoma reaches enrolment target of 40 patientsData updates from...

Multi-centre trial evaluating efti in combination with pembrolizumab and chemotherapy in patients with non-small cell lung cancer reaches enrolment target of approximately 50 evaluable patientsData...

Favourable safety profile for world’s first LAG-3 agonist, IMP761, with no treatment related adverse events to dateAdditional safety data and assessment of PK/PD relationships to follow in first half...